Related Experiment Video

Updated: May 19, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

New therapeutic targets for osteoporosis: beyond denosumab

Vivien Lim1, Bart L Clarke

  • 1Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.

Maturitas
|August 29, 2012
PubMed

Insights

New osteoporosis treatments are emerging beyond antiresorptive drugs. Novel anabolic agents and biologics target bone formation, promising improved bone density and reduced fractures.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Osteoporosis treatments have historically prioritized antiresorptive agents to prevent bone loss.
  • Approved antiresorptive drugs include hormone therapy, bisphosphonates, raloxifene, calcitonin, and denosumab.
  • Current anabolic agents, teriparatide and PTH 1-84, are limited in number.

Purpose of the Study:

  • To review the evolution of osteoporosis treatments.
  • To highlight emerging anabolic and biologic agents targeting bone formation.
  • To discuss the mechanisms and potential of novel osteoporosis therapies.

Main Methods:

  • Review of existing literature on osteoporosis pharmacotherapy.
  • Analysis of current clinical trials for novel osteoporosis agents.
  • Discussion of molecular targets and pathways involved in bone metabolism.

Main Results:

  • Cathepsin K inhibitors show potential for dual antiresorptive and anabolic effects.
  • Biologic agents targeting the Wnt/β-catenin pathway (anti-sclerostin, anti-dickkopf antibodies) are in development.
  • These novel agents stimulate osteoblast activity and promote new bone formation.

Conclusions:

  • Emerging biologic agents offer new mechanisms to stimulate bone formation.
  • These novel therapies aim to increase bone mineral density and decrease fracture risk.
  • The future of osteoporosis treatment involves a broader range of anabolic and targeted biologic interventions.

More Related Videos

Osteoclast Derivation from Mouse Bone Marrow06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...